Update on the therapy of highly aggressive non-Hodgkin’s lymphoma

Bibliography

• VAN DEN BOSCH CA: Is endemic Burkitt’s lymphoma an alliance between three infections and a tumour promoter? Lancet Oncol. (2004) 5(12):738-746.
   PubMed Web of Science ®Google Scholar
• WRIGHT DH: Burkitt’s lymphoma: a review of the pathology, immunology, and possible etiologic factors. Pathol. Ann. (1971) 6:337-363.
   Google Scholar
• BELLAN C, LAZZI S, DE FALCO G, NYONGO A, GIORDANO A, LEONCINI L: Burkitt’s lymphoma: new insights into molecular pathogenesis. J. Clin. Pathol. (2003) 56(3):188-192.
   PubMed Web of Science ®Google Scholar
• RASTI N, FALK KI, DONATI D et al.: Circulating Epstein–Barr virus in children living in malaria-endemic areas. Scand. J. Immunol. (2005) 61(5):461-465.
   PubMed Web of Science ®Google Scholar
• MOORMANN AM, CHELIMO K, SUMBA OP et al.: Exposure to holoendemic malaria results in elevated Epstein-Barr virus loads in children. J. Infect. Dis. (2005) 191(8):1233-1238.
   PubMed Web of Science ®Google Scholar
• GUTIERREZ MI, BHATIA K, BARRIGA F et al.: Molecular epidemiology of Burkitt’s lymphoma from South America: differences in breakpoint location and Epstein-Barr virus association from tumors in other world regions. Blood (1992) 79(12):3261-3266.
   PubMed Web of Science ®Google Scholar
• HARRIS NL, JAFFE ES, DIEBOLD J et al.: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J. Clin. Oncol. (1999) 17(12):3835-3849.
   PubMed Web of Science ®Google Scholar
• GONG JZ, STENZEL TT, BENNETT ER et al.: Burkitt lymphoma arising in organ transplant recipients: a clinicopathologic study of five cases. Am. J. Surg. Pathol. (2003) 27(6):818-827.
   PubMed Web of Science ®Google Scholar
• THIRWELL C, SARKER D, STEBBING J, BOWER M: Acquired immunodeficiency syndrome-related lymphoma in the era of highly active antiretroviral therapy. Clin. Lymphoma (2003) 4(2):86-92.
   PubMedGoogle Scholar
• KIRK O, PEDERSEN C, COZZI-LEPRI A et al.: Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood (2001) 98(12):3406-3412.
   PubMed Web of Science ®Google Scholar
• GATES AE, KAPLAN LD: AIDS malignancies in the era of highly active antiretroviral therapy. Oncology (2002) 16(5):657-665.
   PubMed Web of Science ®Google Scholar
• SUBAR M, NERI A, INGHIRAMI G et al.: Frequent c-myc oncogene activation and infrequent presence of Epstein-Barr virus genome in AIDS-associated lymphoma. Blood (1988) 72(2):667-671.
   PubMed Web of Science ®Google Scholar
• LAZZI S, FERRARI F, NYONGO A: et al. HIV associated malignant lymphomas in Kenya (Equatorial Africa). Hum. Pathol. (1998) 29(11):1285-1289.
   PubMed Web of Science ®Google Scholar
• RUDDELL A, MEZQUITA P, BRANDVOLD KA, FARR A, IRITANI BM: B lymphocyte-specific c-Myc expression stimulates early and functional expansion of the vasculature and lymphatics during lymphomagenesis. Am. J. Pathol. (2003) 163(6):2233-2245.
   PubMed Web of Science ®Google Scholar
• KOMANO J, MARUO S, KUROZUMI K et al.: Oncogenic role of Epstein-Barr virus-encoded RNAs in Burkitt’s lymphoma cell line Akata. (1999) 73(12):9827-9831.
   Google Scholar
• BELLAN C, LAZZI S, HUMMEL M et al.: Immunoglobulin gene analysis reveals two distinct cells of origin for EBV positive and EBV negative Burkitt’s lymphomas. Blood (2005) 106(3):1031-1036.
   PubMed Web of Science ®Google Scholar
• WEBER-NORDT RM, EGEN C, WEHINGER J et al.: Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood (1996) 88(3):809-816.
   PubMed Web of Science ®Google Scholar
• RICHARDSON C, FIELDING C, ROWE M, BRENNAN P: Epstein-Barr virus regulates STAT1 through latent membrane protein 1. J. Virol. (2003) 77(7):4439-4443.
   PubMed Web of Science ®Google Scholar
• GORDADZE AV, ONUNWOR CW, PENG R, POSTON D, KREMMER E, LING PD: EBNA2 amino acids 3 to 30 are required for induction of LMP-1 and immortalization maintenance. J. Virol. (2004) 78(8):3919-3929.
   PubMed Web of Science ®Google Scholar
• BARAN-MARSZAK F, FEUILLARD J, NAJJAR I et al.: Differential roles of STAT1 and STAT1ß in fludarabine-induced cell cycle arrest and apoptosis in human B cells. Blood (2004) 104(8):2475-2483.
   PubMed Web of Science ®Google Scholar
• KANG MS, LU H, YASUI T et al.: Epstein-Barr virus nuclear antigen 1 does not induce lymphoma in transgenic FVB mice. (2005) 102(3):820-825.
   Google Scholar
• NAJJAR I, BARAN-MARSZAK F, LE CLORENNEC C et al.: Latent membrane protein 1 regulates STAT1 through NF-κB-dependent interferon secretion in Epstein-Barr virus-immortalized B cells. J. Virol. (2005) 79(8):4936-4943.
   PubMed Web of Science ®Google Scholar
• CINTI C, CLAUDIO PP, HOWARD CM et al.: Genetic Alterations of the retinoblastoma-related gene RB2/p130 identify different pathogenetic mechanisms in and among Burkitt’s lymphoma subtypes. Cancer Res. (2000) 60(2):383-389.
   PubMed Web of Science ®Google Scholar
• DOUCET JP, HUSSAIN A, AL-RASHEED M et al.: Differences in the expression of apoptotic proteins in Burkitt’s lymphoma cell lines: potential models for screening apoptosis-inducing agents. Leuk. Lymphoma (2004) 45(2):357-362.
   PubMed Web of Science ®Google Scholar
• MEAD GM, SYDES MR, WALEWSKI J et al.: An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann. Oncol. (2002) 13(8):1264-1274.
   PubMed Web of Science ®Google Scholar
• THOMAS DA, CORTES J, O’BRIEN S et al.: Hyper-CVAD program in Burkitt’s-type adult acute lymphoblastic leukemia. J. Clin. Oncol. (1999) 17(8):2461-2470.
   PubMed Web of Science ®Google Scholar
• LACASCE A, HOWARD O, LIB S et al.: Modified Magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. Leuk. Lymphoma (2004) 45(4):761-767.
   PubMed Web of Science ®Google Scholar
• VALNET-RABIER MB, CHALLIER B, THIEBAULT S et al.: c-Flip protein expression in Burkitt’s lymphomas is associated with a poor clinical outcome. Br. J. Haematol. (2005) 128(6):767-773.
   PubMed Web of Science ®Google Scholar
• OYARZO MP, MEDEIROS LJ, ATWELL C et al.: c-FLIP confers resistance to FAS-mediated apoptosis in anaplastic large-cell lymphoma. Blood (2006) 107(6):2544-2547.
   PubMed Web of Science ®Google Scholar
• DE VRIES MJ, VEERMAN AJ, ZWAAN CM: Rituximab in three children with relapsed/refractory B-cell acute lymphoblastic leukaemia/Burkitt non-Hodgkin’s lymphoma. Br. J. Haematol. (2004) 125(3):414-415.
   PubMed Web of Science ®Google Scholar
• CARNAHAN J, WANG P, KENDALL R et al.: Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin. Cancer Res. (2003) 9(10 Pt 2):3982S-3990S.
   PubMed Web of Science ®Google Scholar
• WANG L, GROSSMAN SR, KIEFF E: Epstein-Barr virus nuclear protein 2 interacts with p300, CBP, and PCAF histone acetyltransferases in activation of the LMP1 promoter. Proc. Natl. Acad. Sci. USA (2000) 97(1):430-435.
   PubMed Web of Science ®Google Scholar
• ROYCHOWDHURY S, BAIOCCHI RA, VOURGANTI S et al.: Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder. J. Natl Cancer Inst. (2004) 96(19):1447-1457.
   PubMed Web of Science ®Google Scholar
• SIBON D, GABET AS, ZANDECKI M et al.: HTLV-1 propels untransformed CD4 lymphocytes into the cell cycle while protecting CD8 cells from death. J. Clin. Invest. (2006) 116(4):974-983.
   PubMed Web of Science ®Google Scholar
• PROIETTI FA, CARNEIRO-PROIETTIA B, CATALAN-SOARES BC, MURPHY EL: Global epidemiology of HTLV-I infection and associated diseases. Oncogene (2005) 24(39):6058-6068.
   PubMed Web of Science ®Google Scholar
• JAFFE ES, BLATTNER WA, BLAYNEY DW et al.: The pathologic spectrum of adult T-cell leukemia/lymphoma in the United States. Human T-cell leukemia/lymphoma virus-associated lymphoid malignancies. Am. J. Surg. Pathol. (1984) 8(4):263-275.
   PubMed Web of Science ®Google Scholar
• PLUMELLE Y, PASCALINE N, NGUYEN N et al.: Adult T-cell leukemia-lymphoma: a clinico-pathologic study of twenty-six patients from Martinique. (1993) 7(4):251-262.
   Google Scholar
• NAKASE K, HARA M, KOZUKA T et al.: Bone marrow transplantation from unrelated donors for patients with adult T-cell leukaemia/lymphoma. Bone Marrow Transplant. (2006) 37:41-44.
   PubMed Web of Science ®Google Scholar
• SANADA I, TANAKA R, TSUDA H et al.: Chromosomal aberrations in adult T cell leukemia: relationship to the clinical severity. Blood (1985) 65(3):649-654.
   PubMed Web of Science ®Google Scholar
• AKAGI T, ONO H, SHIMOTOHNO K: Characterization of T cells immortalized by Tax1 of human T-cell leukemia virus Type 1. Blood (1995) 86(11):4243-4249.
   PubMed Web of Science ®Google Scholar
• SODROSKI J, ROSEN C, GOH WC, HASELTINE W: A transcriptional activator protein encoded by the x-lor region of the human T-cell leukemia virus. Science (1985) 228(4706):1430-1434.
   PubMed Web of Science ®Google Scholar
• YOSHIDA M: Multiple viral strategies of HTLV-1 for dysregulation of cell growth control. Annu. Rev. Immunol. (2001) 19:475-496.
   PubMed Web of Science ®Google Scholar
• SUGAHARA K, UEMURA A, HARASAWA H et al.: Clinical relevance of survivin as a biomarker in neoplasms, especially in adult T-cell leukemias and acute leukemias. Int. J. Hematol. (2004) 80(1):52-58.
   PubMed Web of Science ®Google Scholar
• KAWAKAMI H, TOMITA M, MATSUDA T et al.: Transcriptional activation of survivin through the NF-kappaB pathway by human T-cell leukemia virus Type I tax. Int. J. Cancer (2005) 115(6):967-974.
   PubMed Web of Science ®Google Scholar
• SINHA-DATTA U, HORIKAWA I, MICHISHITA E et al.: Transcriptional activation of hTERT through the NF-kappaB pathway in HTLV-I-transformed cells. Blood (2004) 104(8):2523-2531.
   PubMed Web of Science ®Google Scholar
• MATSUDA T, ALMASAN A, TOMITA M et al.: Resistance to Apo2 ligand (Apo2L)/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis and constitutive expression of Apo2L/TRAIL in human T-cell leukemia virus type 1-infected T-cell lines. J. Virol. (2005) 79(3):1367-1378.
   PubMed Web of Science ®Google Scholar
• SATUO Y, NOSAKA K, KOYA Y et al.: Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. Leukemia (2004) 18(8):1357-1363.
   PubMed Web of Science ®Google Scholar
• NASR R, EL-SABBAN ME, KARAM JA et al.: Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma. Oncogene (2005) 24(3):419-430.
   PubMed Web of Science ®Google Scholar
• TAGUCHI H, KINOSHITA KI, TAKASUKI K et al.: An intensive chemotherapy of adult T-cell leukemia/lymphoma: CHOP followed by etoposide, vindesine, ranimustine, and mitoxantrone with granulocyte colony-stimulating factor support. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. (1996) 12(2):182-186.
   PubMedGoogle Scholar
• HERMINE O, ALLARD I, LEVY V et al.: A prospective Phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol. J. (2002) 3(6):276-282.
   PubMedGoogle Scholar
• GILL PS, HARRINGTON W JR, KAPLAN MH et al.: Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N. Engl. J. Med. (1995) 332(26):1744-1748.
   PubMed Web of Science ®Google Scholar
• TOBINAI K, UIKE N, SABURI Y et al.: Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma. Int. J. Hematol. (2003) 77(5):512-517
   PubMed Web of Science ®Google Scholar
• TSUKASAKI K, TOBINAI K, SHIMOYAMA M et al.: Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109). Int. J. Hematol. (2003) 77(2):164-170.
   PubMed Web of Science ®Google Scholar
• MAEDA Y, YANAGUCHI, UEDA S et al.: All-trans retinoic acid reduced skin involvement of adult T-cell leukemia. Leukemia (2004) 18(6):1159-1160.
   PubMed Web of Science ®Google Scholar
• HERMINE O, DOMBRET H, POUPON J et al.: Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. Hematol. J. (2004) 5(2):130-134.
   PubMedGoogle Scholar
• FUKUSHIMA T, MIYAZAKI Y, HONDA S et al.: Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. Leukemia (2005) 19(5):829-834.
   PubMed Web of Science ®Google Scholar
• OKAMURA J, UTSUNOMIYA A, TANOSAKI R et al.: Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma. Blood (2005) 105(10):4143-4145.
   PubMed Web of Science ®Google Scholar
• DE THE G, BOMFORD R: An HTLV-I vaccine: why, how, for whom? AIDS Res. Hum. Retroviruses (1993) 9(5):381-386.
   PubMed Web of Science ®Google Scholar
• OHASHI T, HANABUCHI S, KATO H et al.: Prevention of adult T-cell leukemia-like lymphoproliferative disease in rats by adoptively transferred T cells from a donor immunized with human T-cell leukemia virus Type 1 Tax-coding DNA vaccine. J. Virol. (2000) 74(20):9610-9616.
   PubMed Web of Science ®Google Scholar
• UCHIYAMA T, HORI T, TSUDO M et al. Interleukin-2 receptor (Tac antigen) expressed on adult T cell leukemia cells. J. Clin. Invest. (1985) 76(2):446-453.
   PubMed Web of Science ®Google Scholar
• WALDMANN TA, WHITE JD, GOLDMAN CK et al.: The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood (1993) 82(6):1701-1712.
   PubMed Web of Science ®Google Scholar
• WALDMANN TA, WHITE JD, CARRASQUILLO et al.: Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood (1995) 86(11):4063-4075.
   PubMed Web of Science ®Google Scholar
• ZHANG M, ZHANG Z, GOLDMAN CK et al.: Combination therapy for adult T-cell leukemia-xenografted mice: flavopiridol and anti-CD25 monoclonal antibody. Blood (2005) 105(3):1231-1236.
   PubMed Web of Science ®Google Scholar
• EKLUND JW, KUZEL TM: Denileukin diftitox: a concise clinical review. Expert Rev. Anticancer Ther. (2005) 5(1):33-38.
   PubMed Web of Science ®Google Scholar
• WILLIAMS DP, SNIDER CE, STROM TB et al.: Structure/function analysis of interleukin-2-toxin (DAB486IL-2): Fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J. Biol. Chem. (1990) 265(20):11885-11889.
   PubMed Web of Science ®Google Scholar
• DIVENUTI G, NAWGIRI R, FOSS F: Denileukin diftitox and hyper-CVAD in the treatment of human T-cell lymphotropic virus 1-associated acute T-cell leukemia/lymphoma. Clin. Lymphoma (2003) 4(3):176-178.
   PubMedGoogle Scholar
• RATZINGER G, REAGAN JL, HELLER G et al.: Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. Blood (2003) 101(4):1422-1429.
   PubMed Web of Science ®Google Scholar
• NUCKEL H, FREY UH, ROTH A et al.: Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity. Eur. J. Pharmacol. (2005) 514(2-3):217-224.
   PubMed Web of Science ®Google Scholar
• ZHANG M, ZHANG Z, GOLDMAN CK et al.: Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. Cancer Res. (2003) 63(19):6453-6457.
   PubMed Web of Science ®Google Scholar
• MONE A, PUHELLA S, WHITMAN S et al.: Durable hematological complete response and suppression of HTLV-1 viral load following alemtuzumab in AZT/IFNalpha-refractory adult T-cell leukemia. Blood (2005) 106(10):3380-3382.
   PubMed Web of Science ®Google Scholar
• ISHIDA T, UTSUNOMIYA A, IIDA S et al.: Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma (ATLL): its close association with skin involvement and unfavorable outcome. Clin. Cancer Res. (2003) 9(10 pt 1):3625-3634.
   PubMed Web of Science ®Google Scholar
• ISHIDA T, IIDA S, AKATSUKA Y et al.: The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-cell leukemia/lymphoma. Clin. Cancer Res. (2004) 10(22):7529-7539.
   PubMed Web of Science ®Google Scholar
• CORTES J, O’BRIEN SM, PIERCE S et al.: The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood (1995) 86(6):2091-2097.
   PubMed Web of Science ®Google Scholar
• THOMAS DA, O’BRIEN S, CORTES J et al.: Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood (2004) 104(6):1624-1630.
   PubMed Web of Science ®Google Scholar
• COLGAN JP, ANDERSEN J, HABERMANN TM et al.: Long-term follow-up of a CHOP-based regimen with maintenance therapy and central nervous system prophylaxis in lymphoblastic non-Hodgkin’s lymphoma. Leuk. Lymphoma (1994) 15(3-4):291-296.
   PubMed Web of Science ®Google Scholar
• SWEETENHAM JW, SANTINI G, QIAN W et al.: High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group. J. Clin. Oncol. (2001) 19(11):2927-2936.
   PubMed Web of Science ®Google Scholar
• LEVY JE, HARRIS RE, LOBERIZA FR et al.: A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood (2003) 101(7):2476-2482.
   PubMed Web of Science ®Google Scholar
• JEHA S, GANDHI V, CHAN KW et al.: Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood (2004) 103(3):784-789.
   PubMed Web of Science ®Google Scholar
• KANTARJIAN H, GANDHI V, CORTES J et al.: Phase II clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood (2003) 102(7):2379-2386.
   PubMed Web of Science ®Google Scholar
• KISOR DF, PLUNKETT W, KURTZBERG J et al.: Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a Phase I study of nelarabine for the treatment of refractory hematologic malignancies. J. Clin. Oncol. (2000) 18(5):995-1003.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZ CO, MITCHELL BS, AYRES M et al.: Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Cancer Res. (2002) 62:3100-3105.
   PubMed Web of Science ®Google Scholar
• BERG SL, BLANEY SM, DEVIDAS M et al.: Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children’s Oncology Group. J. Clin. Oncol. (2005) 23(15):3376-3382.
   PubMed Web of Science ®Google Scholar
• DEANGELO D, YU D, DODGE RK et al.: A Phase II study of 2-amino-9-b-D-arabinosyl-6-methoxy-9H-purine (506U78) in patients with relapsed or refractory T-lineage acute lymphoblastic leukiam (ALL) or lymphoblastic lymphoma (LBL): CALGB study 19801. Blood (2002) 100:198a.
   Google Scholar
• WENG AP, FERRANDO AA, LEE W et al.: Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science (2004) 306(5694):269-271.
   PubMed Web of Science ®Google Scholar
• WOLFE MS: Therapeutic strategies for Alzheimer’s disease. Nat. Rev. Drug Discov. (2002) 1(11):859-866.
   PubMed Web of Science ®Google Scholar
• GRAUX C, COOLS J, MELOTTE C et al.: Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat. Genet. (2004) 36(10):1084-1089.
   PubMed Web of Science ®Google Scholar
• SOSLOW RA, BAERGEN RN, WARNKE RA: B-lineage lymphoblastic lymphoma is a clinicopathologic entity distinct from other histologically similar aggressive lymphomas with blastic morphology. Cancer (1999) 85(12):2648-2654.
   PubMed Web of Science ®Google Scholar
• WESTBROOK CA, HOOBERMAN AL, SPINO C et al.: Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762). Blood (1992) 80(12):2983-2990.
   PubMed Web of Science ®Google Scholar
• BRANFORD S, HUGHES T: Detection of BCR-ABL mutations and resistance to imatinib mesylate. Methods Mol. Med. (2006) 125:93-106.
   PubMedGoogle Scholar
• VON BUBNOFF N, MANLEY PW, MESTAN J et al.: Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood (2006) (In Press).
   Google Scholar
• TALPAZ M, KANTARJIAN HM, PAQUETTE R et al.: A Phase I study of BMS-354825 in patients with imatinib resistannt and intolerant chronic phase chronic myeloid leukemia (CML): results for CA180002. Proc. Am. Soc. Clin. Oncol. (2005):564s.
   Google Scholar
• METZLER M, FORSTER A, PANNELL R et al.: A conditional model of MLL-AF4 B-cell tumourigenesis using invertor technology. Oncogene (2006) (In Press).
   PubMedGoogle Scholar
• SHEARER BM, FLYNN HC, KNUDSON RA, KETTERLING RP: Interphase FISH to detect PBX1/E2A fusion resulting from the der(19)t(1;19)(q23;p13.3) or t(1;19)(q23;p13.3) in paediatric patients with acute lymphoblastic leukaemia. Br. J. Haematol. (2005) 129(1):45-52.
   PubMedGoogle Scholar
• JAMIL A, THEIL KS, KAHWASH S et al.: TEL/AML-1 fusion gene. its frequency and prognostic significance in childhood acute lymphoblastic leukemia. Cancer Genet. Cytogenet. (2000) 122(2):73-78.
   PubMed Web of Science ®Google Scholar
• HOLLEMAN A, CHEOK MH, DEN BOER ML et al.: Gene expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N. Engl. J. Med. (2004) 351(6):533-542.
   PubMed Web of Science ®Google Scholar